Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

Aim To assess the efficacy and safety of recently approved once‐weekly glucagon‐like peptide 1 receptor agonists (GLP‐1 RAs) in patients with type 2 diabetes. Methods We conducted a systematic review and meta‐analysis of randomized controlled trials comparing any GLP‐1 RA licensed for once‐weekly do...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes, obesity & metabolism obesity & metabolism, 2015-11, Vol.17 (11), p.1065-1074
Hauptverfasser:	Karagiannis, T., Liakos, A., Bekiari, E., Athanasiadou, E., Paschos, P., Vasilakou, D., Mainou, M., Rika, M., Boura, P., Matthews, D. R., Tsapas, A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Agonists Antidiabetics Clinical trials Confidence intervals Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Dosage Drug Administration Schedule Drug Therapy, Combination Female GLP-1 GLP-1 analogue GLP-1 receptor agonists Glucagon Glucagon-Like Peptide 1 - administration & dosage Glucagon-Like Peptide 1 - agonists Glucagon-Like Peptide 1 - analogs & derivatives Glucagon-Like Peptides - administration & dosage Glucagon-Like Peptides - analogs & derivatives Glycated Hemoglobin A - drug effects Hemoglobin Humans Hypoglycemic Agents - administration & dosage Immunoglobulin Fc Fragments - administration & dosage incretin therapy Incretins - administration & dosage Male Meta-analysis Metformin Metformin - administration & dosage Peptides Peptides - administration & dosage Placebos Randomized Controlled Trials as Topic Recombinant Fusion Proteins - administration & dosage Safety Statistical analysis Systematic review type 2 diabetes Venoms - administration & dosage
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!